Development
Cullinan Therapeutics, Inc.
CGEM
$8.08
$0.141.76%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.49M | 45.14M | 44.25M | 43.03M | 40.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 190.65M | 179.77M | 164.74M | 162.54M | 132.44M |
| Operating Income | -190.65M | -179.77M | -164.74M | -162.54M | -132.44M |
| Income Before Tax | -169.22M | -158.48M | -146.71M | 125.64M | 151.32M |
| Income Tax Expenses | -14.12M | -1.86M | -4.38M | 61.69M | 42.12M |
| Earnings from Continuing Operations | -155.10 | -156.63 | -142.33 | 63.95 | 109.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.94M | 485.00K | 571.00K | 1.40M | 2.02M |
| Net Income | -153.16M | -156.14M | -141.76M | 65.35M | 111.21M |
| EBIT | -190.65M | -179.77M | -164.74M | -162.54M | -132.44M |
| EBITDA | -190.34M | -179.48M | -164.51M | -162.38M | -132.34M |
| EPS Basic | -3.70 | -3.73 | -3.36 | 1.34 | 2.50 |
| Normalized Basic EPS | -2.50 | -2.38 | -2.18 | -2.15 | -1.70 |
| EPS Diluted | -3.72 | -3.75 | -3.38 | 1.21 | 2.37 |
| Normalized Diluted EPS | -2.50 | -2.38 | -2.18 | -2.13 | -1.68 |
| Average Basic Shares Outstanding | 166.16M | 169.12M | 172.00M | 176.92M | 180.67M |
| Average Diluted Shares Outstanding | 166.16M | 169.12M | 172.00M | 178.43M | 182.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |